Haug Partners Successfully Defends Takeda’s Vyvanse® Patents At Trial Against Generic Challenge
Judge Chesler held that all of Takeda’s asserted patents were infringed, not invalid under 35 U.S.C.
- Judge Chesler held that all of Takeda’s asserted patents were infringed, not invalid under 35 U.S.C.
- As a result, Judge Chesler enjoined Defendant Norwich from bringing its generic product to market until August 24, 2023, upon expiration of Takeda’s Pediatric Exclusivity period for Vyvanse®.
- The trial focused on fourteen claims asserted across nine Orange Book-listed patents.
- The Court also afforded significant weight to admissions by Norwich’s Rule 30(b)(6) witnesses elicited during depositions and played at trial.